The cerebral blood volume (CBV) is a crucial physiological indicator of tissue viability and vascular reactivity. Thus, noninvasive CBV mapping has been of great interest. For this, ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, including monocrystalline iron oxide nanoparticles, can be used as long-half-life, intravascular susceptibility agents of CBV MRI measurements. Moreover, CBV-weighted functional MRI (fMRI) with USPIO nanoparticles provides enhanced sensitivity, reduced large vessel contribution and improved spatial specificity relative to conventional blood oxygenation level-dependent fMRI, and measures a single physiological parameter that is easily interpretable. We review the physiochemical and magnetic properties, and pharmacokinetics, of USPIO nanoparticles in brief. We then extensively discuss quantifications of baseline CBV, vessel size index and functional CBV change. We also provide reviews of dose-dependent sensitivity, vascular filter function, specificity, characteristics and impulse response function of CBV fMRI. Examples of CBV fMRI specificity at the laminar and columnar resolution are provided. Finally, we briefly review the application of CBV measurements to functional and pharmacological studies in animals. Overall, the use of USPIO nanoparticles can determine baseline CBV and its changes induced by functional activity and pharmacological interventions.
INTRODUCTION
The cerebral blood volume (CBV) is a crucial physiological indicator of tissue viability and vascular reactivity, as CBV changes are linked directly to the regulation of blood flow under conditions of both normal and abnormal physiology. It is generally thought that dilation and constriction of the blood vessels are the major mechanisms that maintain cerebral blood flow (CBF) within an autoregulatory range, and adjust blood flow to perturbations, such as those induced by CO 2 changes and neural stimulation. Thus, the noninvasive measurement of neurovascular morphology and function is important.
In order to quantify CBV with MRI, an intravascular contrast agent can be utilized. When MR signal intensities are compared before and after the administration of the intravascular contrast agent, the difference is related to the blood volume (1) (2) (3) (4) . Most common approaches for human studies involve the injection of gadolinium diethylenetriaminepentaacetate (Gd-DTPA) into blood as a bolus (2) , and imaging during the first pass of the contrast agent. The delivery of the agent into the brain vasculature is closely related to blood flow, and therefore the onset and peak times of MRI signal changes induced by the contrast agent vary depending on the blood flow characteristics of the tissue. However, a time integral of the MRI time course during the first pass is an index of CBV (5) . As a result of the relatively short blood half-life of Gd-DTPA, its use for dynamic CBV studies is quite limited (3) . Alternatively, iron oxide nanoparticles can be used as a blood pool agent (with a longer half-life than Gd-DTPA) for CBV imaging, and are generally classified into superparamagnetic iron oxide (SPIO) particles with a mean particle diameter of >50 nm, and ultrasmall superparamagnetic iron oxide (USPIO) particles with a smaller hydrodynamic diameter (6) . With the same coating material (e.g. dextran), the former has a much shorter blood half-life than the latter (7) . In order to use these iron oxide nanoparticles for CBV studies, an agent with a relatively long half-life is preferred in order to maintain the same concentration during the experimental duration. Thus, USPIO is the choice for functional CBV studies at steady state, whereas both USPIO and SPIO can be used for baseline CBV and angiographic imaging.
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The relationship between the susceptibility effect and tissue relaxation rate changes can be determined approximately by analytical solutions (8, 9) and by Monte Carlo simulation (10) (11) (12) . Iron oxide particles can be used to determine baseline CBV distribution and to provide insights into vessel size (13, 14) . In the late 1990s, long-half-life USPIO particles were used for functional studies (15) (16) (17) (18) , and Mandeville and colleagues later expanded the use of USPIO for functional and pharmacological MRI studies (19) (20) (21) (22) . This approach to the use of USPIO for functional studies is often referred to as 'increased relaxation for optimized neuroimaging (IRON)' (23) , monocrystalline iron oxide nanoparticle (MION) (24) , CBV-weighted or contrast agent-enhanced functional MRI (fMRI).
In this review, we describe the characteristics of USPIO, baseline CBV and vessel size measurements, functional CBV changes and application of CBV measurements to animal research. However, it is not our intention to review all CBV articles using USPIO, but rather to focus on principles and critical issues related to the quantification of CBV and its change. A recent review article of USPIO applications in animal studies can be found in Wu et al. (25) . It should be emphasized that USPIO distributes into blood plasma; therefore, all quantitative measurements of baseline CBV need to consider hematocrit levels, whereas it is generally assumed that the hematocrit level does not change during relative CBV (rCBV) measurements. All of the following figures were obtained from the cat cortex in our laboratory.
PHYSIOCHEMICAL PROPERTIES AND PHAMACOKINETICS OF IRON OXIDE NANOPARTICLES
Iron oxide nanoparticles contain an iron oxide crystal core with a biodegradable coating. The core size of USPIO is 4-10 nm, and its structure can be a single crystal form (MION) (24) . A hydrophilic polymer coating surrounding the iron oxide core is necessary to provide stability of the iron oxide in aqueous solution, and the common materials used are dextran and its derivatives (e.g. carboxylmethyl dextran). In addition to the hydrodynamic diameter, the coating material and surface charge will influence the blood half-life and biodistribution. Thus, the blood half-life of laboratory-made USPIO can vary between different batches and laboratories. In addition, the blood half-life is dependent on the species and dose. For example, commercially available Feraheme (ferumoxyl; AMAG Pharmaceuticals, Lexington, MA, USA) with a hydrodynamic diameter of 30 nm and a polyglucose sorbitol carboxymethylether coating has a blood half-life of approximately 15 h in humans (Feraheme instruction sheet) and >2 h in rats. In pigs, the blood half-life of dextran-coated MION was found to be approximately 50 min (26) . In our studies, we found that the blood half-life is shorter in cats than in rats. In order to increase the blood half-life, we often infuse dextran solution to compete with dextran-coated USPIO. For most animal studies, a long half-life is preferred to maintain the same concentration during a long experimental time. Many review articles are available on the physiochemical properties, pharmacokinetics and biosafety of USPIO (6, 27, 28) .
If a sterile and isotonic USPIO vial is obtained from commercial vendors (e.g. AMAG Pharmaceuticals), it should be directly injectable into the bloodstream. If USPIO is obtained from academic laboratories, its in vivo use may require further preparations by suspending it in phosphate-buffered saline and filtering through a sterile filter. If the USPIO batch is exposed to high temperatures, its particles may disintegrate and result in a shorter blood half-life.
USPIO nanoparticles are absorbed by the spleen, liver, bone marrow and lymph nodes (7) , and are biodegradable. They are not assumed to have any long-term toxicity. Repeated intravenous injections of MION in monkeys (accumulated dose, 128 mg/kg) for over 1 year did not induce any noticeable side effects (29, 30) . However, repeated injections can increase blood iron levels, which can be removed by an iron chelating agent, such as deferoxamine, which binds free iron in the bloodstream and enhances its elimination.
MAGNETIC PROPERTIES OF IRON OXIDE NANOPARTICLES
Superparamagnetic properties occur when the crystal size is smaller than the ferromagnetic domains (~30 nm) (6) . Furthermore, USPIO nanoparticles possess magnetism only when an external magnetic field is applied, and the induced magnetism is almost saturated at approximately 1 T [see Fig. 4 in ref. (24)] for MION. The magnetism of USPIO is dependent on the core size, so that different production batches may have different core sizes as well as magnetism. A change in proton relaxation rate (unit of s -1 ) caused by iron oxide particles can be described as ΔR 1 = r 1 Â C and ΔR 2 = r 2 Â C, where r 1 and r 2 are the relaxivity constants (s -1 mM -1 ) and C is the iron concentration (mM). It should be noted that 1 mg Fe/mL is equivalent to 17.9 mM Fe. Relaxivity constants can be different in different magnetic fields (B 0 ) [see Fig. 2 in ref. (6) ]. r 1 is robustly determined by a linear fitting of R 1 versus concentration, whereas R 2 versus concentration is slightly nonlinear at high iron concentrations (25) . Thus, the Fe concentration can be determined from ΔR 1 of USPIO solution and r 1 . The relaxivity constants of Feraheme are r 1 = 38 s -1 mM -1 and r 2 = 83 s -1 mM -1 at 20 MHz (0.47 T) (31) . At 1.5 T, r 1 of MION is 13.9 s -1 mM -1 (32) . In our 9.4-T measurements, r 1 of MION was 1-1.7 s -1 mM -1 in saline solution and blood plasma and r 2 was 70-110 s -1 mM -1 in saline solution (33) . r 1 decreases with B 0 , whereas r 2 is almost independent of B 0 . It should be noted that, in order to measure R 1 and R 2 of blood with USPIO, withdrawn blood can be centrifuged and only the plasma fraction retained in order to eliminate the precipitation of red blood cells during MR measurements.
In addition to changes in blood R 1 and R 2 , USPIO induces the susceptibility effect, which can be used to quantify blood volume (see below). The susceptibility effect is closely related to the induced magnetism and Fe concentration. In order to determine the susceptibility effect of USPIO, two capillary tubes filled with saline (one oriented parallel to B 0 and the other perpendicular to B 0 ) are secured inside a cylinder containing a blood-USPIO mixture, and the frequency difference between the peaks originating from each of the capillaries is measured (14, (34) (35) (36) . The spectroscopic frequencies of water peaks originating from parallel-and perpendicular-oriented capillaries (v || and v ⊥ , respectively) immersed in the withdrawn blood differ as a result of both hemoglobin in red blood cells and USPIO in plasma, and their separation can be expressed as v || -v ⊥ = 2pΔw blood+agent n 0 (14, 34, 35) , where Δw blood+agent is the susceptibility difference between the arterial blood containing USPIO and water, and n 0 is the spectrometer resonance frequency. All susceptibility values are expressed in CGS units. As the susceptibility of plasma is similar to that of water (37) (35) . Alternatively, in order to minimize the contribution of hemoglobin, plasma only can be used for susceptibility measurements. In our studies with 15 mg Fe/kg intravenous injection into rats, Δw agent of USPIO in plasma was 0.36 ppm (i.e. corresponding to the frequency shift of 904 Hz at 9.4 T) (36) . As the induced magnetism is saturated at~1 T, most animal studies performed between 4.7 and 11.7 T have similar frequency shifts induced by USPIO. In our studies, the frequency shift induced by USPIO at 9.4 T was found to be 1.1 times that at 4.7 T (33).
QUANTIFICATION OF BASELINE TOTAL BLOOD VOLUME
After USPIO is injected into the bloodstream, a steady-state condition is quickly achieved (7) . Even when a small dose is used (e.g. 1 mg Fe/kg body weight), blood T 1 and T 2 are shortened significantly. In our 9.4-T rat studies (39), 1 mg Fe/kg body weight decreased arterial blood T 2 from 40 to 14 ms, and blood T 1 from 2.30 to 1.14 s. The USPIO intravenous injection dose of 1 mg Fe/kg body weight distributes to 60 mL volume/kg body weight, resulting in an USPIO concentration of~0.017 mg Fe/mL blood (e.g. with a hematocrit level of 40%, an USPIO concentration of 0.028 mg/mL plasma is 0.50 mM). Thus, when a highly T 1 -weighted pulse sequence with a short TE is used, especially at low B 0 , blood vessels can be visualized because of the shortened T 1 . This property has been exploited for angiography (31, 40) .
USPIO has been commonly used for CBV imaging in animals. The relationship between MION doses and R 2 * is important to determine the appropriate dose of USPIO. For this, cats were used to determine the relationship between the tissue R 2 * change and USPIO dose at 9.4 T (33). A dose of 2 mg Fe/kg of USPIO was repeatedly injected into the cat femoral vein until the total dose reached 10 mg/kg. After every injection, T 2 *-weighted images with TEs of 6-40 ms were obtained at a steady-state condition (>2 min after the injection), and R 2 * was calculated. The relationship between ΔR Ã 2;agent of gray matter at 9.4 T and the USPIO injection dose was ΔR (32) .
To measure CBV with USPIO, it is preferable to inject a dose of 5-15 mg Fe/kg to create a large contrast between pre-and post-contrast images, and to obtain sufficient signal intensity of post-contrast T 2 *-weighted images. The signal change induced by USPIO is directly related to the content of iron in a given pixel, and can be converted to ΔR were acquired before and after a bolus injection of 12 mg Fe/kg MION (Fig. 1B, C) . The calculated ΔR 2 * map induced by MION (Fig. 1D) shows exquisite intracortical vessel patterns running into the cortex (42, 43) , low intensity in white matter and high intensity at the cortical surface. Interestingly, the middle part of the cortex has a slightly higher ΔR Ã 2;agent band. This ΔR 2 * value can be converted into CBV under an assumption of the static dephasing domain, as reported previously (8) .
The static dephasing domain is commonly considered to be 1/(frequency shift induced by USPIO) < < R , which, for a 2-mm-radius capillary, is much
For the condition in which static dephasing is dominant, the change in the apparent transverse relaxation rate in tissue caused by the contrast agent, and in the absence of stimulation ðΔR Ã 2;agent Þ (8), can be described as:
where f CBV is the whole blood volume fraction (mL blood/mL brain), which includes both plasma and blood cells, and g is the gyromagnetic ratio, which is 2.675 Â 10 8 rad/(s T). Baseline f CBV (mL/mL) can be determined using Equation [1] from ΔR Generally, it is assumed that susceptibility-induced dephasing effects within a voxel are not influenced by neighboring voxels for CBV estimation. However, this assumption is not valid at a high spatial resolution (e.g. Fig. 1 ). In particular, baseline CBV determined from Equation [1] is overestimated when large vessels in neighboring voxels induce field gradients (see region near cortical surface in Figs 1 and 2E ). An additional assumption is that the origin of the relaxation change is primarily from the extravascular compartment (8) . The USPIO-induced signal change is on the order of approximately 50% in the extravasculature, whereas the intravascular blood signal before the MION injection is only a few per cent, which results in a very small error in CBV values.
A major advantage of USPIO over Gd-DTPA for CBV mapping is the longer blood half-life of USPIO. This allows the acquisition of high-resolution images of the entire brain and dynamic CBV measurements during interventions (see below) without concern for changes in contrast agent concentration. One major issue of USPIO is that it is not approved for human CBV studies, unlike Gd-DTPA. A detailed description of Gd-DTPA measurements can be found in Calamante (5). Compared with gadolinium chelates (about 1 nm in size), USPIO is more likely to remain in the bloodstream because of its larger hydrodynamic diameter, and thus is a better choice for CBV mapping in animals.
MAPPING BASELINE MICROVASCULAR VOLUME AND VESSEL SIZE INDEX (VSI)
The field gradient generated by blood iron oxides decreases by (a/R v ) 2 , where a is the distance from the vessel to the region of interest and R v is the vessel radius. During the TE typically chosen for MRI studies (e.g.~50 ms), water molecules diffuse 10-20
. Thus, phase coherence of water spins near capillaries will be dynamically averaged over the steep field gradients produced by blood USPIO during TE, which cannot be recovered by a 180 radiofrequency pulse, whereas the dephasing effect around large veins can be refocused. Thus, the signal change in T 2 *-weighted images is sensitive to vessels of all sizes, whereas that in T 2 -weighted images is most sensitive to small vessels, where the diffusion contribution is dominant. The vessel size tuning of ΔR 2,agent is sensitive to the USPIO dose (Δw agent ) and TE; a higher dose and shorter TE result in tuning to a smaller vessel diameter (11, 12) . According to Monte Carlo simulations, the tuned vessel diameter is~4 mm for a frequency shift of 160 Hz and TE of 100 ms (corresponding to 900 Hz and TE = 3.2 ms for the same diffusion distance over the same field difference) [see Fig. 2 in ref. (12)]. Both ΔR 2 and ΔR 2 * increase with vessel diameter up to the tuned vessel diameter, but ΔR 2 * is always larger than ΔR 2 . Beyond the tuned diameter, ΔR 2 * plateaus, whereas ΔR 2 decreases with vessel diameter [see Fig. 1 in ref. (12) ]. Thus, ΔR 2 * is sensitive to total CBV, whereas ΔR 2 is an index of microvascular CBV (13, 14) . Figure 2 shows ΔR 2 * and ΔR 2 maps of the cat brain induced by 10 mg Fe/kg MION, obtained using echo planar imaging techniques with a pixel resolution of 156 mm 156 mm Â 2 mm at 9.4 T (45). As shown in Fig. 1D , the surface of the cortex has very high ΔR (Fig. 2E) show the highest ΔR Ã 2;agent at the cortical surface because of large pial vessel contributions, and the highest ΔR 2,agent in the middle of the cortex, which is consistent with previous findings that middle cortical layers have the highest microvascular density (46) . Interestingly, ΔR Ã 2;agent decreases with cortical depth up to~0.5 mm, which is probably a result of the extended dephasing effect from large surface vessels and the partial volume fraction of surface vessels within the slice thickness of 2 mm.
Baseline microvascular volume distribution can be obtained from ΔR 2,agent maps. As angiogenesis is of great interest, baseline CBV studies have often been performed in tumor models. Le Duc et al. (47) obtained ΔR 2,agent maps in normal and glioma-bearing rats, and found a high vessel density in the peripheral area and a low vessel density in the central area of the tumor. Wu et al. (48) measured microvascular volume distribution in mice with an injection of 30 mg Fe/kg at 9.4 T, and found that CBV in the cerebral cortex was higher in transgenic APP mice than in wildtype controls. Dunn et al. (49) used ΔR 2,agent in blood and tissue to determine microvascular volumes during angiogenesis, and compared them with those obtained using in vitro vascular fluorescence microscopy. The microvascular CBV values of control and vasodilated chronic hypoxic rats correlated well with those obtained from microvascular morphology. This indicates that ΔR 2,agent provides relative microvascular volume distribution and is a useful method to investigate angiogenesis.
Assuming that the susceptibility effect remains within a pixel, the pixel ΔR Figure 2D , F shows the VSI map and cortical profile, respectively; the largest VSI is observed in the surface of the cortex, as expected. Assuming that USPIO remains within vessels, VSI has been used to examine the characteristics of angiogenesis (13, 14, 51) . The exact weighted mean radius determined by VSI correlates well with ex vivo micro-computed tomography angiography and histological vessel measurements (52), but is six times larger in tumor and muscle than that obtained from optical microscopic imaging (53 
MAPPING QUANTITATIVE RELATIVE CBV CHANGE
USPIO is ideal for use for CBV-based fMRI studies because of its long blood half-life (15) (16) (17) (18) . Functional CBV-weighted signal changes accompany blood oxygenation level-dependent (BOLD) signal changes. Thus, the signal change induced by stimulation before and after USPIO needs to be examined further. The functional BOLD signal change before USPIO (ΔS pre ) is described as: 3/2 shows a comparatively high ratio of large to small vessels at the cortical surface and within white matter. (E, F) One profile was generated for each animal from the quadrangular regions of interest in area 18 in (A), and the data were averaged across five animals. The surface of the cortex is at zero, with the cortical depth represented by increasing distances. An approximate location of the cortical layers was determined by the relative distances of the layers in area 18 (57) , and is differentiated by colored bands; the middle cortical layer (approximately layer 4) is located in the region between 0.7 and 1.15 mm from the surface of the cortex. (E, F) Cortical depth profiles reflect the distribution of total CBV (ΔR at R Ã 2;pre ÁTE pre = 1.0, and therefore the optimal TE is usually set to the tissue T 2 *. Higher baseline venous CBV increases R Ã 2;pre and ΔR Ã 2;BOLD , but decreases baseline signal intensity (S pre ). Thus, at large vessel regions, the relative functional signal change (ΔS pre =S pre ) can be high, but the absolute functional BOLD signal change (ΔS pre ) decreases at higher fields because of increased R Ã 2;pre and reduced S pre . After USPIO is injected into blood, the baseline signal decreases and the functional signal change contains both CBV-induced USPIO susceptibility changes and deoxyhemoglobin-related BOLD signal changes (16, 45, 54) . The post-agent functional signal change (ΔS post ) is described as:
/mM). It should be noted that r 2 * is almost independent of B 0 . The relative functional signal change (ΔS post /S post ) has a BOLD contribution (ΔS pre /S pre ) and an absolute CBV change term. The BOLD contribution to ΔS post /S post can be corrected using pre-USPIO BOLD data. As C and r 2 * are identical across pixels, the BOLD-corrected functional signal change is directly related to the absolute blood volume change. Then, the rCBV change (ΔCBV/CBV) can be determined as: [5] At higher magnetic fields, the BOLD contribution is not negligible (55) and should be corrected in order to quantify the rCBV changes (16, 45) . The underlying assumption of the BOLD correction is that the BOLD signal change is identical between pre-and post-contrast agent conditions. This assumption is valid only when the intravascular BOLD contribution is minimal, because USPIO suppresses all intravascular signal contributions. If the intravascular BOLD contribution before USPIO injection is significant, the BOLD contribution to CBV-weighted fMRI using Equation [5] is overestimated; thus, the rCBV change (ΔCBV/CBV) is slightly overestimated.
Examples of how to obtain ΔCBV/CBV are shown in Figs 3 and 4 (56) . TE was set to 25 ms and 15 ms for the BOLD and CBV-weighted fMRI studies at 4.7 T, respectively. The baseline T 2 * values of cat gray matter were~51 ms and~21 ms before and after the 7-mg/kg MION injection, respectively. During a visual stimulation period, the largest BOLD signal changes (Fig. 3A) . Following MION injection, the MRI signal decreased during neural stimulation, indicating an increase in CBV (Fig. 3B) . The CBV-weighted signal was confined to the primary visual areas and closely followed the gray matter contour. In contrast with the BOLD signals, the maximum CBV-weighted signals were centered over the gray matter, whereas a significantly smaller signal was detected at the cortical surface. However, the CBV-weighted signal is dependent on the dose of MION and CBV changes, as well as BOLD contributions. Basal CBV levels were obtained by measuring ΔR 2 * induced by MION (Fig. 3C) . Although CBV-weighted fMRI signal changes are negligible in large vessel areas (Fig. 3B) , quantitative rCBV changes (rCBV map) are significant (Fig. 3D ).
More importantly, larger stimulation-induced rCBV changes take place at the center of the cortical gray matter. To better exemplify the properties of the stimulus-induced functional signal changes, their profiles were plotted across cortical layers (Fig. 4) . To correlate the functional maps with the underlying cortical laminar structures, schematic boundaries between cortical layers, based on the literature (57) and previous histological studies (43, 58) , were superimposed (Fig. 4C) . Both rCBV and CBV-weighted signals exhibit elevated signals at middle cortical layers, with smaller changes at upper surface vessels and white matter regions.
As mentioned in the previous section on Mapping Baseline Microvascular Volume and Vessel Size Index (VSI), spin echo (SE) and VSI fMRI approaches can be used to characterize the size of vessels that are functionally responding. To obtain an insight into the hemodynamic regulation, we can assume that baseline CBV total = CBV micro + CBV macro , where CBV micro and CBV macro are the micro-and macrovascular volumes, respectively. As a portion of small arterioles and venules can contribute to these SE measurements, the boundary between micro-and macro-vessels is not well defined. Changes in relative total and microvascular volumes were measured, where stimulation-induced ΔrCBV total = (ΔCBV micro + ΔCBV macro )/(CBV micro + CBV macro ) and ΔrCBV micro = ΔCBV micro /CBV micro . If a change in relatively large vessels is dominant, ΔrCBV micro (measured by SE fMRI) should be very small relative to ΔrCBV total [measured by gradient echo (GE) fMRI]. If a change in the capillary volume is dominant, ΔrCBV micro should be larger than ΔrCBV total . It should be noted that SE measurements underestimate the true microvascular volume change because the sensitivity of vessels larger than the tuned diameter decreases. We reported a 5.6% ΔrCBV micro and a 10% ΔrCBV total in the middle of the cortex (45) , which indicates that most responding vessels are larger than the tuned vessel diameter (capillaries). Similarly, as VSI provides an index of a weighted vessel size, comparison of VSI between the baseline and functional conditions will provide information on the responding vessel sizes. Zhao et al. (45) showed an average ratio of stimulation to baseline VSI values (relative VSI) in the middle of the cortex of 2.80. In other words, if the weighted vessel radius was 2 mm in the middle cortex, the corresponding weighted vessel radius responding to stimulation would be~6 mm. This indicates that dilated vessels responding to neural stimulation are larger than capillaries.
Similar studies were performed in rats by Mandeville et al. (59) . In their studies, higher baseline CBV was consistent with higher baseline ðΔR Ã 2;agent =ΔR 2;agent Þ 3=2 and lower ΔrCBV total /ΔrCBV micro , resulting in a higher baseline VSI and almost constant functional VSI. This indicates that the large vessel responses are not dominant, which is similar to the conclusion made by Zhao et al. (45) . However, functional VSI is much less than baseline VSI, which is consistent with the results at the cortical surface in Zhao et al. (45), but not with the results within the cortex. When ΔS post /S post is calculated from SE fMRI after an USPIO injection, it relates to an absolute change in microvascular CBV, which is always less than the total CBV change. As most vessels are larger than the tuned diameter, its diameter change subquadratically contributes to SE measurements [see sensitivity profile in ref. (12)]. The microvascular CBV change measured by SE fMRI with USPIO underestimates the true change (59) . Thus, SE fMRI should not be used for the accurate determination of the absolute CBV response. 
SENSITIVITY AND SPECIFICITY OF CBV-WEIGHTED VERSUS BOLD FMRI
The functional sensitivity of the CBV-weighted fMRI signal [Equation [4] ] is closely dependent on the dose of USPIO, baseline CBV and BOLD contamination, as well as stimulus duration (30) . As the BOLD contrast increases with B 0 , and the magnetization of iron oxides is saturated above~1.0 T (24), the stimulation-induced signal of CBV-weighted fMRI decreases at higher B 0 because of the counteractive effect of BOLD relative to the CBV response. Generally, with lower B 0 , the functional sensitivity gain over conventional BOLD fMRI increases. B 0 -dependent sensitivity properties were investigated by Mandeville et al. (17) . The reported sensitivity values were measured under a steady-state condition. The CBV-weighted fMRI sensitivity is approximately six times greater than the GE BOLD fMRI signal at 2 T (12 mg Fe/kg, TE = 25 ms) and 1.5-2 times greater at 4.7 T (16 mg/kg, TE = 25 ms) in rats (17) , and three times greater at 3 T in monkeys (8-10 mg/kg, 20 ms for MION versus 30 ms for BOLD) (29, 30) . At 7 T, 15-20 mg/kg USPIO improves the functional contrast-to-noise ratio (CNR) by 70% in rats compared with BOLD (TE = 14 ms for BOLD and USPIO) (60) . At 9.4 T, the improvement in CNR is 1.2-1.5 times in the cat visual cortex (MION of 10 mg/kg, TE of 10-15 ms for CBV-weighted fMRI versus TE of 20 ms for BOLD fMRI) (33). Mandeville et al. (21) reported that CNR in CBV-weighted GE fMRI with 28 mg Fe/kg and TE of 5 ms improved twofold compared with GE BOLD with TE of 10 ms in the rat brain during cocaine stimulation. Very recently, Qiu et al. (61) used USPIO for 3-T human fMRI studies, showing two to three times CNR improvement over GE BOLD in the human visual cortex using a dose of 7 mg/kg. To maximize the sensitivity gain, TE post should be set to 1/R Ã 2;post . The BOLD contribution to CBV-weighted fMRI could also be minimized by using a short TE value.
The sensitivity of CBV-weighted fMRI [Equation [4] ] also depends on the baseline CBV because the baseline signal intensity is related to exp ÀTE post ÁCÁr Ã 2 ÁCBV À Á . This baseline CBVdependent functional sensitivity was examined by Mandeville and Marota (19) . When the USPIO dose and TE are optimized for one baseline CBV value, namely CBV ref , ΔS post is modulated by exp(-CBV/CBV ref ); thus, regions with a large baseline CBV have decreased functional sensitivity. This baseline CBV-dependent function is referred to as a vascular filter (19) .
What is the consequence of the vascular filter on CBV-weighted fMRI? Regions with large vessels lose their baseline signals more rapidly than regions with cortical microvessels, thus less absolute signal changes are induced by the same absolute CBV change. This phenomenon is similar to large vessel regions at long TEs or at very high fields; even if the relative percentage change (TEΔR Ã 2;BOLD ) is quite high, the absolute signal change (ΔS pre ) is low because of the low baseline signal intensity. This mechanism has been proposed to be a major reason for the improvement in the spatial localization (19) . In addition, large BOLD contributions at vessel areas reduce the CBV-weighted signal change. Thus, activation foci in CBV-weighted images obtained as statistical values (or absolute intensities) can shift to deeper cortical areas compared with BOLD fMRI (Fig. 3A versus Fig. 3B and 4A ). Supporting findings have been reported in the rat somatosensory cortex (19) and the monkey visual cortex (62) .
The improved spatial localization of CBV-weighted fMRI may be a result of true physiological responses, rather than just the vascular filter function. This hypothesis can be tested in two ways: (i) by quantifying the rCBV change and comparing it with the CBV-weighted response; and (ii) by comparing measurements with different filter functions. First, to remove baseline signal dependences from the activation maps, percentage signal changes from baseline (ΔS/S) are calculated (see Fig. 4B ), and then the BOLD contribution is corrected. Peak positions in CBV-weighted ΔS (blue trace in Fig. 4A ), CBV-weighted ΔS/S (blue trace in Fig. 4B ) and rCBV changes (green trace in Fig. 4B ) within the cortex remain the same. Second, SE versus GE fMRI with USPIO shows peak responses in the middle of the cortex and independence from the vascular filter functions (45) . Third, three MION doses of 5, 10 and 15 mg Fe/kg were used at TE = 10 ms at 9.4 T. The peak positions of the CBV-weighted fMRI response remain the same with different MION doses (see Fig. 5 ). A similar finding was reported by Keilhotz et al. (63) , in which spin-echo fMRI was performed on the rat somatosensory cortex with 10, 20 and 30 mg Fe/kg at 11.7 T. The spatial peak of the percentage signal changes in CBV-weighted fMRI was invariant of the dose of MION and pulse ) and CBV-weighted fMRI (%), cortical profiles were obtained (E, F) from the green regions of interest in (A). When the dose of MION was increased from 5 to 15 mg/kg, a steeper ΔR sequence, indicating that the improved spatial localization of CBVweighted fMRI is a result of true physiological responses.
SENSITIVITY OF CBV-WEIGHTED FMRI VERSUS DOSE OF USPIO
The choice of USPIO dose is critical to maximize the functional sensitivity. Two conditions can be considered: (i) TE post = TE pre = 1/R 2 * ,pre ; and (ii) TE post < TE pre . For condition (i), the USPIO dose is optimal when the baseline signal decreases to e -1 of the precontrast intensity [ Fig. 5a in ref. (19) ] at TE post ÁCÁr Fig. 5b in ref. (19) ]. The sensitivity gain of condition (ii) relative to condition (i) is exp(-TE post /TE pre ) [ Fig. 5b in ref. (19) ]. Most CBV-weighted fMRI studies use the latter condition.
During long experimental times, the USPIO blood concentration decreases and, consequently, functional CBV-weighted ΔS/S similarly decreases. Figure 6 shows time courses of CBV-weighted fMRI signals more than 2 h after the administration of 10 mg Fe/kg MION (64) . For this specific and early application of MION in our laboratory, additional dextran solution (to increase the blood half-life of dextran-coated MION) was not infused, unlike the remainder of our cat experiments. Positive BOLD responses and negative CBV-weighted responses were consistently obtained from area 18 of the cat visual cortex. As the MION concentration in blood decreased by clearance processes, the CBV contrast diminished accordingly. To remove iron concentration-dependent variations, an index of baseline Fe concentration ( ΔR Ã 2;agent ) should be measured, and used for the determination of the rCBV change [see Equation [5] ]. Thus, baseline ΔR Ã 2;agent at each time course was calculated from baseline data. When rCBV changes were calculated with BOLD correction (Fig. 6B) , CBV time courses were similar. In particular, when the concentration of MION in the blood is low, the BOLD correction is essential to determine functional rCBV changes.
CHARACTERIZATIONS OF CBV-WEIGHTED FUNCTIONAL RESPONSES
Evoked CBV changes have an initial fast increase, followed by slow increases during long stimulation (65, 66) . It should be noted that, although functional CBV-weighted changes are negative, the absolute changes are used for comparison with BOLD responses. The impulse response function (IRF) of CBV-weighted fMRI differs from that of BOLD fMRI. Silva et al. (66) measured IRF in the rat somatosensory cortex at 11.7 T, and found that the CBV response started and peaked~0.5 s earlier than the BOLD response. Leite et al. (30) systematically determined IRFs of CBV-weighted and BOLD fMRI of visual cortex in awake monkey at 3 T. When a 4-s stimulation was used, both CBV-weighted and BOLD responses peaked at a similar time, but the CBV-weighted signal returned to baseline after the stimulus offset more slowly relative to BOLD fMRI. However, when the stimulation duration was 60 s, the firstorder time constants of the responses were 4.5 s for BOLD and 13.5 s for CBV-weighted fMRI. This indicates that a long stimulation duration increases the functional sensitivity of CBV-weighted fMRI relative to BOLD fMRI (30) , and that the CBV-weighted signal responding to long stimulation cannot be explained by a time-invariant linearity function with the IRF obtained from short stimulation (67) .
As CBV-weighted fMRI provides higher sensitivity than BOLD fMRI, it can be used for high-resolution fMRI studies in animals. In order to examine time-dependent CBV-weighted fMRI, CBV-weighted fMRI images were obtained at 2-s intervals following each stimulation onset (see Fig. 7) . The CBV change initially shows significant radial vessel contributions (see Fig. 7A, B) , following dominant responses in the middle of the cortex (see Fig. 7D ), indicating that a later response is highly specific (68) . For CBV-weighted fMRI with a resolution of 98 Â 98 Â 1000 mm (70), rat whisker barrel cortex showed the highest response to whisker stimulation in layer 4, similar to c-Fos expression maps. These studies indicate that the functional CBV response is quite specific to small functional structures.
The specificity of the CBV response at a cortical columnar scale has been examined by our laboratory (56, 71, 72) . The CBV-weighted fMRI approach with 10 mg Fe/kg and a resolution Figure 6 . Experimental time-dependent functional MRI (fMRI) and relative cerebral blood volume (rCBV) time courses during the decay of monocrystalline iron oxide nanoparticle (MION) contents (89) . fMRI responses of the cat visual cortex induced by visual stimulation were performed from the green region of interest (inset image) before and after an injection of 10 mg/kg MION at 4.7 T (TE = 20 ms, TR = 0.5 s). MION was removed more quickly from blood when an additional dextran solution was not infused in cats (note that all other cat studies used additional dextran solution). The negative change in (A) indicates that the CBV-weighted response is much larger than the positive BOLD contribution. rCBV changes were calculated using BOLD and MION time courses with Equation [5] , showing that the time-dependent variations in CBV-weighted fMRI can be removed. Horizontal bars underneath the time courses indicate the stimulus duration.
of 156 Â 156 Â 1000 mm 3 was applied to map cat orientation columns at 9.4 T (71,72), which could not be obtained with conventional BOLD fMRI under the same animal model and experimental conditions (73) . Figure 8 shows the subtraction maps of 0 and 90 stimulation. Clearly, activations responding to 0 stimulation (red crosses) are not in the same location as those of 90 stimulation. Regions of large CBV changes responding to two orthogonal orientation gratings were highly complementary, indicating that parenchymal CBV responses are quite specific to neural active sites in a steady-state condition (71, 72) . To further examine functional CBV responses at the columnar and laminar level, we employed the well-established ocular dominance column model (74) . Following 7 mg Fe/kg administration, functional CBV-weighted images were acquired with a resolution of 156 Â 156 Â 2000 mm 3 and TE of 15 ms at 4.7 T (56). Figure 9 shows statistical maps for binocular and monocular CBV-weighted activation maps from two cats to demonstrate the consistency of our findings. During binocular stimulation, a more homogeneous pattern of increased CBV was observed along the middle cortical layers. On the contrary, during monocular stimulation, local patches of increased CBV-weighted signals were observed. In all cases, the contralateral hemisphere to the stimulated eye exhibited a larger number of activated pixels (58.1 AE 3.7%; n = 5). Patches of localized increases in blood volume were arranged in an orderly fashion across the middle layers throughout the primary visual cortex. The mean distance between A contiguous cluster size of three active pixels was imposed. The t-value threshold was t > 5 for (A) and was adjusted between 10 and 13.5 to provide a similar number of activated pixels for (B-D). The middle cortical layer is indicated by red arrows. Clearly, the later CBV response is more specific to the middle of the cortex. Blue/purple bar, t value. the centers of adjacent peaks at the medial parts of the lateral gyrus (area 17) was 0.57 AE 0.14 mm (n = 4 cats, total of 124 pairs). Territories dominated by the left eye and the right eye clearly alternated. These results indicate that CBV is regulated at a columnar and laminar level.
APPLICATION TO NEUROVASCULAR AND NEUROSCIENCE RESEARCH
The use of USPIO is ideal to determine dynamic CBV changes induced by ischemia and global stimulation. The earliest applications were to measure CBV changes during ischemia (75) (76) (77) . Many vascular reactivity studies followed, whereby breathing gas was manipulated (78) (79) (80) (81) . USPIO was applied to obtain neural activation-induced fMRI (16) (17) (18) 69) . Although USPIO was used for preliminary human fMRI studies (61) , it is currently not approved as a blood pool agent for humans. Thus, we focus our literature review on animal studies. A common application of CBV-weighted fMRI is to determine the underlying BOLD mechanism and to enhance fMRI sensitivity in animals. As BOLD fMRI is related to a combination of CBF, cerebral metabolic rate of O 2 utilization (CMRO 2 ) and CBV responses, measurements of the CBV response can help to determine the CBV contribution to BOLD (16) and the CMRO 2 change (82-86). To determine the CMRO 2 change with BOLD biophysical models, it is crucial to determine the relationship between ΔCBF/CBF and ΔCBV/CBV (87), which can be expressed as ΔCBV/CBV = (ΔCBF/CBF) a , where a is a constant. Measured a values are dependent on brain regions and time after the stimulus onset (68, 84, 88) . At a steady-state condition, the a values obtained during neural stimulation are 0.43 (84) and 0.19-0.23 (88) in the rat somatosensory cortex and~0.2 in the cat visual cortex (68) . In both rat studies [3 T, 12 mg Fe/kg, TE = 27.2 ms for ref. (84) and 7 T, 8 mg Fe/kg, TE = 20 ms for ref. (88) ], the BOLD contribution to CBV-weighted fMRI was not corrected, and thus the CBV change was slightly underestimated. An important point is that the BOLD signal is directly related to the venous CBV change, not the total CBV change. fMRI with USPIO measures the total CBV change, which is much larger than the venous CBV change (36, 43, 89, 90) . Thus, when the total CBV is used, the contribution of CBV to BOLD signals is overestimated and, consequently, the CMRO 2 change is underestimated. To separate the total CBV into arterial and venous CBV, arterial CBV measurement techniques (39, 91, 92) can be combined with USPIO studies.
As the use of USPIO can enhance functional sensitivity, it is often employed for monkey fMRI studies (29, 30, 93) . In nonhuman primate studies, human MR scanners are often used and experimental time is limited. Thus, an increase in the functional sensitivity is of high priority. Vanduffel et al. (29) , Durand et al. (94) and Tsao et al. (95) and their colleagues routinely use USPIO for monkey fMRI studies. These neuroscience applications are beyond the scope of this review article. For rodent fMRI studies, as high-field animal MRI systems are becoming widely available and BOLD fMRI can be used, CBV-weighted fMRI is less frequently used for neuroscience research relative to its use in nonhuman primate studies. Mueggler et al. (96) used USPIO to image functional activity in transgenic mice, and Zhao et al. (97, 98) used USPIO to image pain responses in the spinal cord and cortex.
USPIO has been used for pharmacological MRI, which investigates hemodynamic responses induced by drugs, because of its high sensitivity and its measurement of a single physiological parameter. The groups of Bruce Jenkins and Marcus Rudin have led pharmacological MRI studies with USPIO. Pharmacological challenges included bicuculline (g-aminobutyric acid antagonist) (96, 99) , cocaine (dopamine transporter inhibitor) (23, (100) (101) (102) , dopamine D2/D3 receptor agonists and antagonists (103, 104) , nicotine (105) , N-methyl-D-aspartate receptor agonists (106), acetylcholine-esterase inhibitor (107) and amphetamine (dopamine releaser) (108, 109) .
CONCLUSIONS
CBV mapping with intravascular, long-half-life USPIO offers new imaging approaches for animal research. Although USPIO is not currently approved for human CBV studies, Feraheme (AMAG Pharmaceuticals) is approved for iron deficiency anemia treatments in humans. Thus, the approval of USPIO as a blood pool agent in humans may be possible in the near future. With USPIO, baseline CBV and its changes induced by functional activity and pharmacological intervention can be reliably and easily determined with high sensitivity, even at low magnetic fields. CBV-weighted fMRI provides enhanced sensitivity, reduced large vessel contribution and improved spatial specificity relative to BOLD fMRI, and measures a single physiological parameter, which is easily interpretable.
